Studies | Therapeutic regimen | Sample size | Infection | Gastrointestinal symptoms | Elevated liver enzymes | Blood system changes | Hair loss | Irregular menstruation | Total |
---|---|---|---|---|---|---|---|---|---|
Hogg 2015 [19] | MMF | 23 | 0 | 2 | 0 | 0 | 0 | 0 | 2 |
Placebo | 27 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | |
Liu 2014 [18] | MMFÂ +Â prednisone | 42 | 2 | 0 | 0 | 0 | 0 | 0 | 2 |
CTXÂ +Â prednisone | 42 | 2 | 3 | 1 | 1 | 1 | 3 | 11 | |
Liu 2010 [17] | MMFÂ +Â prednisone | 20 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
LEFÂ +Â prednisone | 20 | 0 | 1 | 1 | 0 | 0 | 0 | 2 | |
Bao 2007 | MMFÂ +Â prednisone | 19 | 2 | 2 | 0 | 1 | 0 | 0 | 5 |
CTXÂ +Â prednisone | 18 | 3 | 4 | 1 | 2 | 2 | 2 | 13 | |
Frich 2005 | MMF | 17 | 0 | 2 | 0 | 0 | 0 | 0 | 2 |
Placebo | 15 | 0 | 2 | 0 | 1 | 0 | 0 | 3 | |
Tang 2005 [13] | MMF | 20 | 3 | 2 | 0 | 2 | 0 | 0 | 7 |
Placebo | 20 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Baes 2004 | MMF | 21 | 1 | 2 | 0 | 1 | 0 | 0 | 4 |
Placebo | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |